Key Record Dates Identifier: NCT01754870
Brief Title: Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy Followed by Maintenance Rituximab (Rituxan®) and Lenalidomide (Revlimid®) in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)

First Submitted : November 27, 2012
First Submitted that Met QC Criteria : December 18, 2012
First Posted : December 21, 2012 (Estimate)

Last Update Submitted that Met QC Criteria : July 22, 2015
Last Update Posted : July 23, 2015 (Estimate)